HPC DS Injection

Indications

Pregnant women who use HPC DS Injection are less likely to deliver their babies too soon by reducing the risk of premature labor (preterm birth). In women who have already experienced one premature birth, it lowers the risk of premature birth and prevents miscarriage. Only doctors or those working under their supervision may administer HPC DS Injections. You should consider it to be medical advice. Your doctor will determine how much medication you require and for how long. As long as it has been prescribed for you, you should administer this injection.

Pharmacology

The mechanism by which progesterone prevents preterm delivery is unknown, despite the fact that many potential pathways are involved. Progesterone regulates the female reproductive system and is crucial for successful embryo implantation and pregnancy maintenance. It binds to progesterone receptors in numerous organs, including the uterus, ovaries, breasts, and central nervous system, to accomplish this. Neither PR-A nor PR-B has a single isoform. Progesterone, which these receptors bind, controls the transcription of genes.

Dosage & Administration

A progestin is HPC DS Injection (female hormone). It functions by regulating the mother’s immune response to stop the embryo from being rejected and to enable its attachment to the uterus. In women who have already experienced one premature birth, this helps reduce the risk of miscarriage and lowers the likelihood of premature birth.

Administer 500 mg or 250 mg intramuscularly once a week. Start the course of treatment between 16 weeks and 20 weeks and 6 days after conception. Maintain weekly administration until week 37 (36 weeks, 6 days through delivery), whichever comes first.
 

Administration-

• Clean the ampoule top with an alcohol swab before use.
• Draw up 1 ml of drug into a 2 ml syringe.
• After preparing the skin, inject in the upper outer quadrant of the gluteus maximus. The solution is viscous and oily. Slow injection (over one minute or longer) is recommended.
• Applying pressure to the injection site may minimize bruising and swelling.
• Your doctor or nurse will give you this medicine. Kindly do not self-administer.

Contraindications

• There is now or has previously been thrombosis or thromboembolic disease.
• Breast cancer, additional hormone-sensitive cancers, or a history of these conditions in the family.
• Undiagnosed abnormal vaginal bleeding not connected to pregnancy.
• Jaundice brought on by cholestatic pregnancy.
• Liver tumors, either benign or cancerous, or active liver disease.
• Uncontrolled hypertension.

Side Effects

• Hives
• Itching
• Nausea
• Diarrhea
• Nodules are the most common injection site effects (pain, edema, pruritus, nodule). If you have any of the following symptoms, contact your doctor immediately:

Inform your doctor immediately if you have pain in the chest, groin, or legs, difficulty with breathing, sudden severe headache, slurred speech, sudden unexplained shortness of breath, a sudden loss of coordination, or vision changes while using this medicine.

Pregnancy & Lactation

Pregnancy is classified as Category B. There are no sufficient and well-controlled trials in pregnant women during the first trimester. In a trial of pregnant women receiving the medicine during their second and third trimesters, as well as a follow-up safety analysis of their infants, teratogenic risks to infants following in-utero exposure to the drug were not demonstrated. It is not meant to interrupt active premature labor; the drug’s impact in this situation is uncertain.

Lactation: Progestins were found in detectable concentrations in the breast milk of women using progestins. Progestins have no negative effects on breastfeeding performance, infant health, growth, or development. At 37 weeks of pregnancy or when the baby is born, stop taking the medicine.

Precautions & Warnings

• Thromboembolic disorders: Discontinue if thrombosis or thromboembolism occurs.
• Allergic reactions: Consider discontinuing if allergic reactions occur. Decreased glucose tolerance: Monitor pre-diabetic and diabetic women receiving HPC.
• Fluid retention: Monitor women with conditions that may be affected by fluid retention, such as pre-eclampsia, epilepsy, and cardiac or renal dysfunction.
• Depression: Monitor women with a history of clinical depression; discontinue HPC if depression recurs.
• Jaundice: Carefully monitor women who develop jaundice while receiving HPC and consider whether the benefit of use warrants continuation.
• Hypertension: Carefully monitor women who develop hypertension while receiving HPC and consider whether the benefit of use warrants continuation.
• Blood Sugar: It may affect blood sugar levels. Monitor your blood sugar regularly.

Storage Conditions

Store between 15°C and 30°C at a controlled room temperature. Protects against the light. Keep out of children’s reach.